shutterstock_175968083.jpg

About

Passion. Experience. Diligence.

 
 

Leadership

 
 
Jason Vaughn.jpg

Principal

Jason M. Vaughn, Ph.D.

Dr. Jason M. Vaughn has 17 years of pharmaceutical development experience. He spent several years at PharmaForm LLC in various positions including Associate Director of Analytical and Formulation Development, Director of Operations and eventually Vice President of Operations. In these positions, he focused on the development of novel abuse deterrent formulations for internal and external clients. He then joined DPT Laboratories as Director of Formulation Development where he led a team that developed formulations for liquids and semisolids. Following this, he joined Enavail LLC as Director of Research. In 2012, Jason joined Patheon as Director of Scientific Affairs in the Cincinnati facility leading the development of formulations focused on modified release oral dosage forms. Jason transferred to Banner Life Sciences as Vice President of Pharmaceutical Development where he focused on novel formulations for the treatment of clinical unmet needs. Finally, Jason transferred back to Patheon as Vice President, Process and Technology Development before starting Wyatt Pharma Consulting. He is currently Senior Vice President, Technical Operations at Avadel Pharmaceuticals (AVDL) where he leads all CMC activities, drug product development and manufacturing.

 

Education

University of Texas at Austin
Ph.D. Pharmaceutics, 2005

University of Texas at Austin
B.S. Pharmacy, 2000

Areas of Expertise

  • Development and commercialization of complex oral drug delivery systems including delayed release, sustained release, targeted release via multparticulate systems, encapsulation and tableting technologies

  • Small particle technology to enhance dissolution rates and bioavailability.

  • Particle engineering technologies and formulation development of nanoparticles for oral and pulmonary delivery

  • Hot-melt extrusion as a method to formulate solid dispersions for controlled release and films for transmucosal delivery

  • Abuse deterrent technologies for prevention of opioid abuse and inadvertent dose dumping

  • Preformulation, formulation and characterization of novel delivery systems for pulmonary, nasal and buccal delivery.

  • Analytical method development, transfer, qualification and validation